Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

InSilico Medicine (ISM HK): AI-Powered Drug Discovery Drives 2025 Result; Signs New Deal with Lilly

InSilico Medicine (3696 HK): Pipeline Is Progressing; 1H Sales Jump 4x on BD Deals; Turns Profitable

Insilico Medicine IPO: Shortening Drug Discovery Period Through AI-Driven Platform Holds Promise

InSilico Medicine (英矽智能) IPO: AI Assets as Upside

Insilico Medicine Pre-IPO - An Emerging AI-Enabled Drug Discovery Platform

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/insilico-medicine-cayman-topco" target="_blank" data-smartkarma-citation="entities:39890:1" rel="noopener">InSilico Medicine Cayman TopCo (ISM HK)</a> shares rallied more than 200% since debut on HK stock exchange. The rally is backed by successive deals stuck with renowned pharmaceutical companies.</li>
<li>InSilico Medicine and China Medical System Holdings entered into a strategic partnership to advance a series of AI-empowered drug discovery collaborations across multiple projects in CNS and autoimmune diseases.</li>
<li>Insilico’s AI-driven platform validated by rapidly bringing multiple drug candidates to IND enabling and clinical stage and business development expertise leading to multiple out-licensing collaborations entail long-term growth prospect.</li>
</ul>



InSilico Medicine Cayman TopCo (ISM HK) shares rallied more than 200% since debut on HK stock exchange. The rally is backed by successive deals stuck with renowned pharmaceutical companies.
InSilico Medicine and China Medical System Holdings entered into a strategic partnership to advance a series of AI-empowered drug discovery collaborations across multiple projects in CNS and autoimmune diseases.
Insilico’s AI-driven platform validated by rapidly bringing multiple drug candidates to IND enabling and clinical stage and business development expertise leading to multiple out-licensing collaborations entail long-term growth prospect.


InSilico Medicine (ISM HK): Firing on Both Cylinders